

# PeriVision: Accessible & efficient eye tests for the 21<sup>st</sup> century

**Sector** | Diagnostics (Dx) / B2B / medtech (ophthalmology / neurology)

**Tech** | AI / VR / software

**Stage** | Seed

**Round size** | min. CHF 2M (~USD 2.3M), potentially up to CHF 3.5M (~USD 4M)

**Use of funds** | Commercialize 1<sup>st</sup> product (US, EU), extend platform (AI prognostics)

**Deck** | [Docsend link](#)

**Web** | [www.perivision.com/about](http://www.perivision.com/about)

**Contact** | [patrick@perivision.com](mailto:patrick@perivision.com)



## Large unmet need

Millions suffer from eye conditions leading to vision loss, e.g. glaucoma (~100M) or AMD (~196M). But current eye tests are inefficient, expensive and unreliable, creating bottlenecks, limiting access and destroying precious sight.

## Growth drivers

Demand for eye tests is increasing dramatically (e.g. by 25% by 2030 in the US) due to demographic & lifestyle trends, while supply & HC resources stagnate.

## Solution

We build VR eye tests and AI diagnostics & prognostics tools to increase clinic productivity, provide deeper insights for clinical decisions and broaden patient access. Product demo video: [LinkedIn](#).

## Value proposition

Our eye tests are fully automated, 70% faster due to proprietary testing algorithms, 26–39% more reliable (i.e. lower data variability), comparable to gold standards and allow clinics to see up to 30% more patients.

## IP / differentiation

We achieve this based on a unique AI IP portfolio (patents, trade secrets, data) of optimized eye tests and AI diagnostics / prognostics tools developed with the University Hospital Bern and validated in clinical studies.

## Traction

Our 1<sup>st</sup> VR eye test (visual fields for glaucoma) is approved as a software as a medical device (SaMD) in the US, UK and EU; ~CHF 0.5M (~USD 0.6M) revenue for 2024, incl. collaborations with the UK NHS and Roche.

## Market

Eye test platform addresses CHF 5B (~USD 5.8B) market, incl. new segments like neurology, opticians, elderly homes or biopharma; strong growth due to demographic and lifestyles trends leading to higher prevalence.

## Fundraising

Raised CHF 1M CLA with several early-stage VCs and FOs, looking for a min. CHF 2M (~USD 2.3M) seed round by Q4 2024 to accelerate our US and EU GTM and expand platform features. Deck: [Docsend](#).

## Team & board

Combining world-class technical and clinical expertise with decades of industry experience at leading companies in our space. Extensive bios: [website](#).



**Patrick Kessel,**  
**Co-founder, CEO, board chairman**  
Strategy consulting in medtech, biopharma & insurance at BCG  
B.A. HSG, MSc. LSE



**Dr. Serife Kucur Ergunay,**  
**Co-founder, CTO, board member**  
6+ years experience in AI research in ophthalmology and glaucoma  
MSc. EPFL, PhD University of Bern



**Prof. Dr. Raphael Sznitman,**  
**Co-founder, board member**  
Professor for AI in Medicine, co-founder RetinAI  
MSc. & PhD John Hopkins University

## Videos by the founders on the vision, technology and its applications



Serife on glaucoma, visual field tests and PeriVision's solution



Raphael on patient monitoring & AI co-pilots (at 6min 50sec)



Patrick on at-home eye tests in clinical trials (at 2h 32min)

## Awards / prizes

